Category: CVD Prevention

Heart Health Month: The Menopause Transition and Its Effects on Cardiometabolic Risk

Cardiovascular disease (CVD) continues to be the leading cause of death among women who experience a notable increase in disease risk after menopause. Female patients tend to develop coronary heart disease several years later than men leading experts to believe that the menopause transition (MT) contributes to an increase in cardiometabolic risk. However, only 56% of women are aware of this association, according to data from a 2012 survey by the American Heart Association (AHA) and that from a 2017 Women’s Heart Alliance study.

In the clinical setting, physicians often apply the same guidelines to patients regardless of their sex although, overwhelming evidence underscores the existence of significant sex differences in the pathophysiology of cardiovascular disease. While the number of clinical trials that include women as participant subjects has grown, a comprehensive gender-specific analysis of both the efficacy and adverse effects of pharmacological and non-pharmacological interventions is lacking.

Read more

Heart Health Month: Current State of Heart Failure Prevention and Treatment

February marks the beginning of Heart Health Month an annual celebration raising awareness for cardiovascular disease and promoting global heart health, during which we will be spotlighting clinically topical areas of cardiovascular medicine.

Current statistics indicate that approximately 6.2 million adults in the United States have heart failure (HF) with a continuously rising prevalence over time due to an increasing aging population. This condition is estimated to cost the nation billions of dollars annually in healthcare services, medications, and missed days of work. While the body of evidence informing the prevention and treatment methods for cardiovascular disease grows, acute heart failure continues to be a challenge.

Read more